NCT04420598
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: Patients must have tumors that are either HER2+ (IHC 3+) or HER2-low (defined as IHC 1+ or 2+ & ISH-negative); HER2+ patients must have been previously treated with a taxane and at least one HER2-targeted therapy in the metastatic setting; HER2-low patients that are also HR-negative must have been previously treated with at least one chemotherapy regimen; HER2-low patients that are also HR+, must have been previously treated with at least one chemotherapy and one endocrine regimen in the metastatic setting
Exclusions: Patients with prior treatment of trastuzumab deruxtecan (Enhertu)
https://ClinicalTrials.gov/show/NCT04420598